UBS Oncology Impact Fund
5
106M
4
1
0.20
3
- Areas of investment
Summary
The standard case for the fund is to invest in rounds with 6 partakers. Despite the UBS Oncology Impact Fund, startups are often financed by SunStates Fund, Samsara BioCapital, Redmile Group. The meaningful sponsors for the fund in investment in the same round are Samsara BioCapital, Redmile Group, EcoR1 Capital. In the next rounds fund is usually obtained by Samsara BioCapital, Redmile Group, EcoR1 Capital.
The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2019. The common things for fund are deals in the range of more than 100 millions dollars.
Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, Oncorus Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Biotechnology, Medical. The fund has exact preference in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 1
- Exits
- 3
- Follow on index
- 0.20
- Investments by industry
- Biotechnology (5)
- Therapeutics (4)
- Health Care (3)
- Pharmaceutical (2)
- Medical (1) Show 3 more
- Investments by region
-
- United States (3)
- Canada (2)
- Peak activity year
- 2019
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cullinan Oncology | 03 Oct 2017 | Biotechnology, Medical Device, Biopharma | Early Stage Venture | 150M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.